OHDSI Home
|
Forums
|
Wiki
|
Github
Researchers
About the Researchers category
(1)
Feasibility of Network studies that use the NOTE, NOTE_NLP, and Flowsheets
(3)
Study launch: Evaluating the Iodine-131 exposure effect on the occurrence of secondary cancer in survivors of thyroid cancer
(2)
How to find the ancestor_concept_id of the condition_concept_id in the condition_occurrence table?
(13)
Has the homepage address changed? (http://omop.org/HOI)
(3)
CDC Collaboration
(3)
Cohort pathway ： why in the same first circle，the same drug sometimes tend to be in central， sometimes tend to be for second circel?
(2)
Adding a new cohort from Synthea generated csv files to an existing CDM
(3)
The meaning of 'minDaysAtRisk' argument
(3)
Standardizing procedures (call for non-US based collaborators)
(18)
Dexamethasone Cohort Building
(4)
Cohort pathway: the unreasonable proporation
(3)
Hematology projects?
(3)
CohortMethod user group
(
2
3
4
)
(73)
Cohort pathway: why Persons with pathways portion are not equal to 100%?
(5)
Empty cohort issue only occurred on KNN, Naive Bayes, Neural Network, DeepNN model
(5)
Atlas: How to set index date to absolute day or to get_todays_date()
(4)
Negative information in OMOP CDM
(11)
Atlas Cohort Definition (Eligibility requirement of more than 1 occurrence of a diagnosis)
(4)
Research Collaboration: NANOTIZED HERBAL MEDICINE FOR BURNS- FROM CONCEPT TO APPLICATION
(1)
Feature Analysis/Cohort Characterization Tool in ATLAS
(3)
COVID-19 study-a-thon data
(1)
COVID-19 infections in cancer patients
(12)
[COVID-19] Prior immunization as protective for COVID-19 disease/bad outcomes
(3)
ICU data, anyone?
(19)
[OHDSI Covid19] Literature review on viral prediction models
(
2
)
(23)
Characterization of Oral Antibiotic and Isotretinoin Therapy for Acne
(4)
Forming external controls for comparative effectiveness estimation
(3)
Do your Rx dispensation data have refills? (USA vs other countries)
(6)
[Covid-19] Alpha-1 blocker as potential prophylaxis against ARDS
(
2
)
(22)
next page →
t
